These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 3018955)

  • 1. An IgM lupus anticoagulant that neutralizes the enhancing effect of phospholipid on purified endothelial thrombomodulin activity--a mechanism for thrombosis.
    Freyssinet JM; Wiesel ML; Gauchy J; Boneu B; Cazenave JP
    Thromb Haemost; 1986 Jun; 55(3):309-13. PubMed ID: 3018955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Circulating lupus-type anticoagulant, a risk factor for thrombosis by inhibition of protein C activation].
    Cariou R; Tobelem G; Caen J
    C R Acad Sci III; 1986; 303(4):113-8. PubMed ID: 3019490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lupus anticoagulant--antiphospholipid antibodies and thrombophilia. Relation to protein C--protein S--thrombomodulin.
    Tsakiris DA; Settas L; Makris PE; Marbet GA
    J Rheumatol; 1990 Jun; 17(6):785-9. PubMed ID: 2167370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of lupus anticoagulant on antithrombogenic properties of endothelial cells--inhibition of thrombomodulin-dependent protein C activation.
    Cariou R; Tobelem G; Bellucci S; Soria J; Soria C; Maclouf J; Caen J
    Thromb Haemost; 1988 Aug; 60(1):54-8. PubMed ID: 2847352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acquired protein C dysfunction but not decreased activity of thrombomodulin is a possible marker of thrombophilia in patients with lupus anticoagulant.
    Pötzsch B; Kawamura H; Preissner KT; Schmidt M; Seelig C; Müller-Berghaus G
    J Lab Clin Med; 1995 Jan; 125(1):56-65. PubMed ID: 7822946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein C.
    Esmon CT
    Prog Hemost Thromb; 1984; 7():25-54. PubMed ID: 6099583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Protein C, protein S and thrombomodulin: one of the natural antithrombotic mechanisms].
    Lobato-Mendizábal E; Ruiz-Argüelles GJ
    Rev Invest Clin; 1990; 42(1):54-62. PubMed ID: 2173090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IgG reactivity to phospholipid-bound beta(2)-glycoprotein I is the main determinant of the fraction of lupus anticoagulant activity quenched by addition of hexagonal (II) phase phospholipid in patients with the clinical suspicion of antiphospholipid-antibody syndrome.
    Safa O; Crippa L; Della Valle P; Sabbadini MG; Viganò D'Angelo S; D'Angelo A
    Haematologica; 1999 Sep; 84(9):829-38. PubMed ID: 10477458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activated protein C resistance and lupus anticoagulant activity induced by plasma and purified monospecific human IgG anti-beta2-glycoprotein-I antibodies.
    Viveros ME; Cabiedes J; Reyes E; Cabral AR
    Rev Invest Clin; 2005; 57(4):563-71. PubMed ID: 16315641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of protein C activation by endothelial cells in the presence of lupus anticoagulant.
    Cariou R; Tobelem G; Soria C; Caen J
    N Engl J Med; 1986 May; 314(18):1193-4. PubMed ID: 3083259
    [No Abstract]   [Full Text] [Related]  

  • 11. The role of beta 2-glycoprotein I-dependent lupus anticoagulants in the pathogenesis of the antiphospholipid syndrome.
    Arnout J
    Verh K Acad Geneeskd Belg; 2000; 62(5):353-72. PubMed ID: 11144685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelet activation induced by combined effects of anticardiolipin and lupus anticoagulant IgG antibodies in patients with systemic lupus erythematosus--possible association with thrombotic and thrombocytopenic complications.
    Nojima J; Suehisa E; Kuratsune H; Machii T; Koike T; Kitani T; Kanakura Y; Amino N
    Thromb Haemost; 1999 Mar; 81(3):436-41. PubMed ID: 10102474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoclonal immunoglobulin M lambda coagulation inhibitor with phospholipid specificity. Mechanism of a lupus anticoagulant.
    Thiagarajan P; Shapiro SS; De Marco L
    J Clin Invest; 1980 Sep; 66(3):397-405. PubMed ID: 6772673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural anticoagulant proteins and antiphospholipid antibodies in systemic lupus erythematosus.
    Tomás JF; Alberca I; Tabernero MD; Cordero M; Del Pino-Montes J; Vicente V
    J Rheumatol; 1998 Jan; 25(1):57-62. PubMed ID: 9458203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of rare anti-phospholipid/protein co-factor autoantibodies in patients with systemic lupus erythematosus.
    Szodoray P; Tarr T; Tumpek J; Kappelmayer J; Lakos G; Poor G; Szegedi G; Kiss E
    Autoimmunity; 2009 Sep; 42(6):497-506. PubMed ID: 19626489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of annexin-V to demonstrate the role of phosphatidylserine exposure in the maintenance of haemostatic balance by endothelial cells.
    Ravanat C; Archipoff G; Beretz A; Freund G; Cazenave JP; Freyssinet JM
    Biochem J; 1992 Feb; 282 ( Pt 1)(Pt 1):7-13. PubMed ID: 1311563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. "Lupus" anticoagulant and thrombosis--possible role of inhibition of prostacyclin formation.
    Carreras LO; Vermylen JG
    Thromb Haemost; 1982 Aug; 48(1):38-40. PubMed ID: 6813993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticardiolipin, anti-beta(2)-glycoprotein I, antiprothrombin antibodies, and lupus anticoagulant in patients with systemic lupus erythematosus with a history of thrombosis.
    Swadzba J; De Clerck LS; Stevens WJ; Bridts CH; van Cotthem KA; Musial J; Jankowski M; Szczeklik A
    J Rheumatol; 1997 Sep; 24(9):1710-5. PubMed ID: 9292792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coextraction of thrombomodulin and tissue factor from human placenta: effects of concanavalin A and phospholipid environment on activity.
    Freyssinet JM; Brami B; Gauchy J; Cazenave JP
    Thromb Haemost; 1986 Feb; 55(1):112-8. PubMed ID: 3010487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Gla26 residue of protein C is required for the binding of protein C to thrombomodulin and endothelial cell protein C receptor, but not to protein S and factor Va.
    Nishioka J; Ido M; Hayashi T; Suzuki K
    Thromb Haemost; 1996 Feb; 75(2):275-82. PubMed ID: 8815576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.